GT BIOPHARMA, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
GT BIOPHARMA, INC. (GTBP) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of -$4.52 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2023-03-30
- GT BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2021-12-31 was $0.00.
- GT BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2021 was -$4.52M, a 185.68% decline from fiscal 2020.
- GT BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2020 was $5.27M, a 3237.97% increase from fiscal 2019.
- GT BIOPHARMA, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2019 was $158.00K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$4.52M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$4.52M 10-Q · filed 2022-10-31 | ||
| 2020-12-31 | $5.27M 10-K · filed 2021-04-16 | ||
| 2019-12-31 | $158.00K 10-K · filed 2021-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |